Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- ...

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Inflammatory mediators like cytokines and chemokines play a key role in driving age-related and postmenopausal breast cancer progression and immune system changes.

Age-related and postmenopausal breast cancer progression remains a significant challenge, with growing evidence pointing to the role of pro-inflammatory cytokines and CXC chemokines in tumor ...

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

The immunosuppressive tumor microenvironment (TME) poses a critical barrier to the efficacy of immune checkpoint inhibitors in triple-negative breast cancer (TNBC). Here, we report a self-assembled ...